Barbosa joined the AG Bio-Pharma leadership team in May 2018 as Vice President of Pharmaceuticals, bringing with him more than 35 years of management and leadership experience in biopharmaceutical production, quality assurance and compliance. He then assumes the role of senior vice president of corporate strategy in 2021, followed by the role of executive vice president of operations in 2022. As President and Chief Operating Officer of Aji Bio-Pharma US, he is responsible for overseeing all aspects of CDMO. Business in US site.
Blagg joins Aji Bio-Pharma with 34 years of experience providing leadership in cross-functional operations in regulated industries, including 23 years in the biopharmaceutical sector. He has served in various senior leadership roles at Revance Therapeutics, PDL Biopharma, and XOMA Corporation, as well as being a respected industry consultant. As Executive Vice President of Operations, Blagg is responsible for Pharmaceuticals, Drug Substances, Labeling/Packaging and Facilities/Engineering Operations.
Katayama began his career at Ajinomoto in 1994 as a process chemist for the CDMO business. He then held a senior research role until 2015, when he became General Manager of the Process Chemistry Group of Bio-Fine Laboratories. In 2017, Katayama moved to the Ajinomoto Group’s headquarters in Tokyo and began working in the Biopharmaceutical Services Department as General Manager of the Planning (Strategy) Group. As Vice President of Business Transformation, he supports the business strategy and harmonization of global Ag Bio-Pharma.
Riley joined Aji Bio-Pharma in August 2017 as Director of Financial Planning and Analysis, bringing more than 25 years of experience including corporate and business unit management experience in global, local and start-up environments. In 2022, Riley became Vice President of Corporate Strategy and in 2023, Senior Vice President of Corporate Planning. In this new role, he is responsible for developing strategic goals for the organization while overseeing human resources, finance and supply chain/procurement.
About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization, based in Belgium, USA, Japan and India, engaged in end-to-end development, cGMP manufacturing and aseptic manufacturing for APIs and small molecule intermediates and large Provides fill-finishing services. Ajinomoto Bio-Pharma Services offers a wide range of innovative platforms and capabilities for preclinical and pilot programs at commercial volumes, including Corynex® Protein Expression Technology, Oligonucleotide Synthesis, Antibody Drug Conjugation (ADCs), High Potency API (HPAPI) , biocatalysis, include continuous. flow creation, and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet the needs of its customers.
